Kelly King

Biomarker testing in non–small cell lung cancer evolves with new protein-based markers and AI, enhancing personalized treatment strategies for patients.

The FDA prioritizes Orca-T's review for treating hematologic malignancies, promising improved survival and reduced complications compared with traditional therapies.